World Health Organization Sounds Concern Over Severe Scarcity of Weight-Loss Injections

Under 10% of individuals that would benefit from weight-loss injections like Wegovy can access them, warns the WHO as it publishes its first guidance on the therapies.

Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.

Per forecasts, more than two billion could be obese by 2030 without intervention.

"The latest guidelines acknowledges that excess weight is a lifelong illness that can be addressed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are key hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, explains the agency.

GLP-1 Therapy Scarcity

Even under the current most favorable outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.

The advice urges governments and firms to expand access, via approaches including licensing agreements.

A patent on a key compound – the core ingredient of a leading brand – is due to expire in several nations in 2026.

How Weight-Loss Drugs Function

GLP-1 drugs imitate a natural hormone to delay gastric emptying, curb appetite and increase feelings of fullness so users consume fewer calories.

People commonly start to lose weight in the initial weeks of beginning the weekly injections.

Research indicates users may regain a significant portion within a year of stopping the medication, when their normal hunger resume.

Being overweight or obese elevates your risk for contracting health problems, like type 2 diabetes, heart disease, brain attack, and specific cancers.

Obesity concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.